Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Provides Update on Phase 3 ASCENT-07 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces Third Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces Second Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.